Arca
Skip to content

Myocardial infarction

Drug research and approvals for myocardial infarction: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 427 studies of myocardial infarction are recruiting on ClinicalTrials.gov, Health Canada has authorized 27 drug trials for it since 2013, and the EU has 20 authorised medicines for it.

  • Recruiting worldwide: 427
  • Trials authorized in Canada: 27
  • FDA orphan approvals: 0
  • EU medicines: 20

Recruiting Now

Newest start dates first, of 427 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 27; search them all in Canada trials
Nov 5, 2025Evaluation of an aspirin-free strategy with ticagrelor in patients with a myocardial infarction treated medically alone (pantheon) [placebo controlled]TICAGRELOR / ACETYLSALICYLIC ACIDMONTREAL HEART INSTITUTEOngoing
Feb 20, 2024Artemis - effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction.ZILTIVEKIMABNovo NordiskOngoing
Aug 22, 2023Randomized, double-blind, placebo-controlled study to investigate a single administration of bi 765845 on top of standard of care in patients with acute…BI 765845BOEHRINGER INGELHEIM (CANADA) LTD LTEEOngoing
Jun 22, 2022A phase 3 prospective, blinded, randomized, placebo controlled, international multicenter study to assess the safety and efficacy of a single subcutaneous…ZALUNFIBANCELECOR THERAPEUTICS, INC.Closed
Dec 16, 2021Iocyte ami-3: a phase 3, randomized, double-blind, placebo-controlled, multicenter study of intravenous fdy-5301 in patients with an anterior st-elevation…FDY-5301FARADAY PHARMACEUTICALS, INC.Closed
Aug 18, 2021Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous…SELATOGREL (ACT-246475)ViatrisOngoing
Dec 16, 2020Empact-mi: a streamlined, multicentre, randomised, parallel group, doubleblind placebo-controlled superiority trial to evaluate the effect of empagliflozin on…EMPAGLIFLOZINBoehringer Ingelheim Pharmaceuticals, Inc.Closed
Nov 27, 2020Rivaroxaban in type 2 myocardial infarctions: a feasibility, placebo-controlled, double-blinded, randomized controlled trialRIVAROXABANGOVERNORS OF THE UNIVERSITY OF ALBERTAClosed
Sep 9, 2020A phase IIb, randomized, double-blinded, placebo-controlled, parallel-group study to evaluate the efficacy and safety of medi6570 in participants with a prior…MEDI6570AstraZeneca Pharmaceuticals LPOngoing
Aug 12, 2020Sonothrombolysis in patients with an st-segment elevation myocardial infarction with fibrinolysis (sonostemi-lysis) trialPERFLUTRENGOVERNORS OF THE UNIVERSITY OF ALBERTAClosed

Medicines Authorised in the EU

Newest first; 15 of 20
Jul 24, 2026Colchicine Agepha PharmacolchicineAgepha Pharma s.r.o.EMA ↗
May 15, 2018Prasugrel Viatris (previously Prasugrel Mylan)prasugrel · genericViatris LimitedEMA ↗
Jan 11, 2016Eptifibatide Accordeptifibatide · genericAccord Healthcare S.L.U.EMA ↗
Feb 18, 2015Clopidogrel ratiopharmclopidogrel · genericTeva B.V.EMA ↗
Dec 3, 2010BriliqueticagrelorAstraZeneca ABEMA ↗
Oct 28, 2010Clopidogrel HCSclopidogrel · genericHCS bvbaEMA ↗
Mar 14, 2010Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover)clopidogrel;acetylsalicylic acidSanofi-Aventis GroupeEMA ↗
Oct 16, 2009Clopidogrel Viatris (previously Clopidogrel Taw Pharma)clopidogrel · genericViatris LimitedEMA ↗
Sep 28, 2009Zylltclopidogrel · genericKRKA tovarna zdravil d.d. Novo mestoEMA ↗
Sep 23, 2009Clopidogrel Krkaclopidogrel · genericKRKA tovarna zdravil d.d. Novo mestoEMA ↗
Sep 23, 2009Clopidogrel TADclopidogrel · genericTad Pharma GmbHEMA ↗
Sep 21, 2009Clopidogrel Taw Pharma (previously Clopidogrel Mylan)clopidogrel · genericTaw Pharma (Ireland) LimitedEMA ↗
Sep 21, 2009Clopidogrel BGR (previously Zylagren)clopidogrel · genericBiogaranEMA ↗
Sep 20, 2009Clopidogrel Krka d.d. (previously Zopya)clopidogrel · genericNorpharm Regulatory Services LtdEMA ↗
Jul 27, 2009Grepidclopidogrel · genericPharmathen S.A.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.